 AUSTIN, Texas--BUSINESS WIRE--Genprex, Inc. Nasdaq: GNPX Genprex or the Company, a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced it has entered into a securities purchase agreement with a single healthcare-dedicated institutional investor for the purchase and sale of 3,116,884 shares of its common stock at a purchase price of 3.85 per share in a registered direct offering priced at-the-market u 